Cited 0 times in
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 신동호 | - |
dc.contributor.author | 안철민 | - |
dc.contributor.author | 임의 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍명기 | - |
dc.date.accessioned | 2018-08-28T17:15:46Z | - |
dc.date.available | 2018-08-28T17:15:46Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0300-8932 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/162417 | - |
dc.description.abstract | INTRODUCTION AND OBJECTIVES: Current guidelines on the treatment of blood cholesterol recommend continuous maintenance of high-intensity statin treatment in drug-eluting stent (DES)-treated patients. However, high-intensity statin treatment is frequently underused in clinical practice after stabilization of DES-treated patients. Currently, the impact of continuous high-intensity statin treatment on the incidence of late adverse events in these patients is unknown. We investigated whether high-intensity statin treatment reduces late adverse events in clinically stable patients on aspirin monotherapy 12 months after DES implantation. METHODS: Clinically stable patients who underwent DES implantation 12 months previously and received aspirin monotherapy were randomly assigned to receive either high-intensity (40mg atorvastatin, n = 1000) or low-intensity (20mg pravastatin, n = 1000) statin treatment. The primary endpoint was adverse clinical events at 12-month follow-up (a composite of all death, myocardial infarction, revascularization, stent thrombosis, stroke, renal deterioration, intervention for peripheral artery disease, and admission for cardiac events). RESULTS: The primary endpoint at 12-month follow-up occurred in 25 patients (2.5%) receiving high-intensity statin treatment and in 40 patients (4.1%) receiving low-intensity statin treatment (HR, 0.58; 95%CI, 0.36-0.92; P = .018). This difference was mainly driven by a lower rate of cardiac death (0 vs 0.4%, P = .025) and nontarget vessel myocardial infarction (0.1 vs 0.7%, P = .033) in the high-intensity statin treatment group. CONCLUSIONS: Among clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | Spanish, English(Summary) | - |
dc.publisher | Elsevier España | - |
dc.relation.isPartOf | REVISTA ESPANOLA DE CARDIOLOGIA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Eui Im | - |
dc.contributor.googleauthor | Yun-Hyeong Cho | - |
dc.contributor.googleauthor | Yongsung Suh | - |
dc.contributor.googleauthor | Deok-Kyu Cho | - |
dc.contributor.googleauthor | Ae-Young Her | - |
dc.contributor.googleauthor | Yong Hoon Kim | - |
dc.contributor.googleauthor | Kyounghoon Lee | - |
dc.contributor.googleauthor | Woong Chol Kang | - |
dc.contributor.googleauthor | Kyeong Ho Yun | - |
dc.contributor.googleauthor | Sang-Yong Yoo | - |
dc.contributor.googleauthor | Sang-Sig Cheong | - |
dc.contributor.googleauthor | Dong-Ho Shin | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.identifier.doi | 10.1016/j.rec.2017.06.008 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A02097 | - |
dc.contributor.localId | A02269 | - |
dc.contributor.localId | A03394 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04391 | - |
dc.relation.journalcode | J02623 | - |
dc.identifier.eissn | 1579-2242 | - |
dc.identifier.pmid | 28716428 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1885585717303171 | - |
dc.subject.keyword | Coronary artery disease | - |
dc.subject.keyword | Drug-eluting stent | - |
dc.subject.keyword | Enfermedad coronaria | - |
dc.subject.keyword | Estatina | - |
dc.subject.keyword | Statin | - |
dc.subject.keyword | Stent farmacoactivo | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.alternativeName | Kim, Byeong Keuk | - |
dc.contributor.alternativeName | Kim, Jung Sun | - |
dc.contributor.alternativeName | Shin, Dong Ho | - |
dc.contributor.alternativeName | Ahn, Chul Min | - |
dc.contributor.alternativeName | Im, Eui | - |
dc.contributor.alternativeName | Jang, Yang Soo | - |
dc.contributor.alternativeName | Choi, Dong Hoon | - |
dc.contributor.alternativeName | Hong, Myeong Ki | - |
dc.contributor.affiliatedAuthor | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | Kim, Byeong Keuk | - |
dc.contributor.affiliatedAuthor | Kim, Jung Sun | - |
dc.contributor.affiliatedAuthor | Shin, Dong Ho | - |
dc.contributor.affiliatedAuthor | Ahn, Chul Min | - |
dc.contributor.affiliatedAuthor | Im, Eui | - |
dc.contributor.affiliatedAuthor | Jang, Yang Soo | - |
dc.contributor.affiliatedAuthor | Choi, Dong Hoon | - |
dc.contributor.affiliatedAuthor | Hong, Myeong Ki | - |
dc.citation.volume | 71 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 423 | - |
dc.citation.endPage | 431 | - |
dc.identifier.bibliographicCitation | REVISTA ESPANOLA DE CARDIOLOGIA, Vol.71(6) : 423-431, 2018 | - |
dc.identifier.rimsid | 60001 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.